Boxer Capital LLC Acquires Shares of 608,614 Arvinas, Inc. (NASDAQ:ARVN)

Boxer Capital LLC acquired a new stake in shares of Arvinas, Inc. (NASDAQ:ARVN) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 608,614 shares of the company’s stock, valued at approximately $25,051,000. Arvinas makes up about 1.3% of Boxer Capital LLC’s holdings, making the stock its 24th biggest position.

A number of other hedge funds also recently bought and sold shares of ARVN. Commodore Capital LP purchased a new stake in shares of Arvinas in the fourth quarter worth approximately $41,160,000. Avidity Partners Management LP lifted its position in shares of Arvinas by 14.2% in the fourth quarter. Avidity Partners Management LP now owns 2,985,117 shares of the company’s stock worth $122,867,000 after purchasing an additional 370,157 shares in the last quarter. Wasatch Advisors LP lifted its position in shares of Arvinas by 7.9% in the fourth quarter. Wasatch Advisors LP now owns 222,942 shares of the company’s stock worth $9,176,000 after purchasing an additional 16,233 shares in the last quarter. Bellevue Group AG lifted its position in shares of Arvinas by 18.0% in the fourth quarter. Bellevue Group AG now owns 2,507,731 shares of the company’s stock worth $103,218,000 after purchasing an additional 382,531 shares in the last quarter. Finally, Personal CFO Solutions LLC purchased a new stake in shares of Arvinas in the fourth quarter worth approximately $206,000. 95.19% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ARVN shares. Wells Fargo & Company reduced their price target on shares of Arvinas from $63.00 to $60.00 and set an “overweight” rating for the company in a research report on Thursday, May 9th. Oppenheimer reissued an “outperform” rating and issued a $80.00 price target (down from $95.00) on shares of Arvinas in a research report on Wednesday, February 28th. HC Wainwright reissued a “buy” rating and issued a $87.00 price target on shares of Arvinas in a research report on Friday, May 17th. Truist Financial reaffirmed a “buy” rating and set a $65.00 price objective on shares of Arvinas in a research report on Monday, March 25th. Finally, Leerink Partnrs reaffirmed an “outperform” rating on shares of Arvinas in a research report on Thursday, February 22nd. Two analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Arvinas has a consensus rating of “Moderate Buy” and a consensus price target of $61.13.

Arvinas Stock Down 0.2 %

Shares of ARVN stock opened at $26.45 on Friday. Arvinas, Inc. has a 12 month low of $13.57 and a 12 month high of $53.08. The business’s 50 day moving average is $32.89 and its two-hundred day moving average is $37.97. The company has a market cap of $1.81 billion, a PE ratio of -4.53 and a beta of 1.98.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.45. Arvinas had a negative return on equity of 64.79% and a negative net margin of 185.09%. The company had revenue of $25.30 million for the quarter, compared to the consensus estimate of $32.94 million. During the same quarter last year, the company posted ($1.54) earnings per share. The company’s revenue for the quarter was down 22.2% compared to the same quarter last year. As a group, equities analysts expect that Arvinas, Inc. will post -4.08 EPS for the current fiscal year.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.